DGAP-Ad hoc: MOLOGEN AG

DGAP-Adhoc: MOLOGEN AG: Verlustanzeige nach §92 Absatz 1 Aktiengesetz

MOLOGEN AG / Key word(s): Preliminary Results/Legal Matter

11.07.2016 17:20

Disclosure of an inside information according to Article 17 MAR, transmitted by DGAP - a service of EQS Group AG. The issuer is solely responsible for the content of this announcement.

---------------------------------------------------------------------------

Ad-hoc notification according to § 15 WpHG

MOLOGEN AG: Report of loss pursuant to section 92 para 1 of the German Stock Corporation Act

Berlin, July 11, 2016. Pursuant to Section 92 Para. 1 of the German Stock Corporation Act (AktG), the Executive Management Board of MOLOGEN AG (ISIN DE0006637200/WKN 663720) indicates that the Company's provisional registered share capital is down to just EUR10,681,859.09 as of June 30, 2016 dated July 11, 2016 as a result of losses incurred. This means that half the Company's share capital of EUR22,631,501.00 has been wiped out by losses. The losses mostly result from the Company's ordinary activities as a research-based biotechnology company which is still developing and without revenues of its own.

In the invitation to the Annual General Meeting which takes place on August 11, published on July 5, 2016 in the German Federal Gazette (Bundesanzeiger), the Executive Management Board has already announced under item 2 of the Agenda that a loss amounting to half the Company's share capital was likely by the day of the Annual General Meeting at the latest. The Executive Management Board will indeed report an actual loss amounting to half the share capital at the Annual General Meeting and discuss this together with a funding proposal. The Company's unaudited interim results to June 30, 2016 will be submitted to the Annual General Meeting. They will also be made available on the Company's website at http://www.mologen.com/en/investor-relations-press/annual-general- meeting.html and will also be made available for shareholder inspection at the Annual General Meeting.

- End of the ad-hoc notification -

DISCLAIMER

This announcement does not constitute an offer to buy shares or other securities of MOLOGEN AG and does not replace the prospectus. Investment decisions with respect to the shares or other securities of MOLOGEN AG shall only take place on the basis of the prospectus which will be available after the approval by the German Financial Supervisory Authority (BaFin) free of charge at MOLOGEN AG. This announcement does not contain or constitute an offer of, or the solicitation of an offer to buy or subscribe for, securities to any person in the United States of America (the "United States"), Australia, Canada or Japan or in any jurisdiction to whom or in which such offer or solicitation is unlawful. The securities referred to in this announcement will not be and have not been registered under the U.S. Securities Act of 1933, as amended (the "U.S. Securities Act") and may not be offered or sold in the United States absent registration or an applicable exemption from registration requirements under the U.S. Securities Act. Subject to certain exceptions, the securities referred to in this announcement may not be offered or sold in Australia, Canada or Japan, or to, or for the account or benefit of, any national, resident or citizen of Australia, Canada or Japan. The offer and sale of the securities referred to in this announcement has not been and will not be registered under the U.S. Securities Act or under the applicable securities laws of Australia, Canada or Japan. There will be no public offer of the securities in the United States.

Contact Claudia Nickolaus Head of Investor Relations & Corporate Communications Tel: +49 - 30 - 84 17 88 - 38 Fax: +49 - 30 - 84 17 88 - 50 investor@mologen.com

Note about risk for future predictions Certain information in this report contains forward-looking statements or the corresponding statements with negation or versions deviating from this or comparable terminology. These are described as forward-looking statements. In addition, all of the information given here that refers to planned or future results of business areas, key financial figures, developments of the financial situation or other financial figures or statistical data, is to be understood as such forward-looking statements. The company points out to investors that they should not rely on these forward-looking statements as predictions about actual future events. The company is not obligated and refuses to accept any liability for the forward-looking statements and has no obligation to update such statements in order to accurately reflect the current situation.

11.07.2016 The DGAP Distribution Services include Regulatory Announcements, Financial/Corporate News and Press Releases. Archive at www.dgap.de

--------------------------------------------------------------------------- Language: English Company: MOLOGEN AG Fabeckstraße 30 14195 Berlin Germany Phone: 030 / 841788-0 Fax: 030 / 841788-50 E-mail: presse@mologen.com Internet: www.mologen.com ISIN: DE0006637200 WKN: 663720 Listed: Regulated Market in Frankfurt (Prime Standard); Regulated Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich, Stuttgart End of Announcement DGAP News-Service ---------------------------------------------------------------------------